In Re Omega Healthcare Inv'rs, Inc. SEC. Litig.

968 F.3d 204
Court of Appeals for the Second Circuit·Decided August 3, 2020·No. 19-1095·Published·Cited by 60 cases

Opinion

19-1095 In re Omega Healthcare Inv’rs, Inc. Sec. Litig.

UNITED STATES COURT OF APPEALS FOR THE SECOND CIRCUIT

August Term 2019

(Argued: November 13, 2019 | Decided: August 3, 2020)

Docket No. 19-1095

ROYCE SETZER,

Lead Plaintiff-Appellant, EARL HOLTZMAN,

Plaintiff-Appellant,

DROR GRONICH, Individually and on behalf of all others similarly situated, Plaintiff,

STEVEN KLEIN, Individually and on behalf of all others similarly situated, Consolidated Plaintiff,

v.

OMEGA HEALTHCARE INVESTORS, INC., C. TAYLOR PICKETT, ROBERT O.

STEPHENSON, DANIEL J. BOOTH,

Defendants-Appellees.

Before:

LEVAL, WESLEY, and LIVINGSTON, Circuit Judges.

Plaintiffs-Appellants brought this putative class action against Omega Healthcare Investors, Inc., a publicly traded real estate investment trust that invests in healthcare facilities, and against Omega’s chief executives, asserting claims under Section 10(b) and 20(a) of the Securities Exchange Act of 1934, 15 U.S.C. §§ 78j(b), 78t(a), and Rule 10b-5, 17 C.F.R. § 240.10b–5. Plaintiffs claim that Omega misled investors by failing to disclose a $15 million working capital loan it made to one of its major tenants, Orianna Health Systems. According to Plaintiffs, this omission hid from investors the true magnitude of Orianna’s solvency problems. The district court dismissed Plaintiffs’ claims for, among other reasons, insufficiently alleging scienter.

Because we find that the complaint adequately alleges that Omega acted with the requisite scienter in failing to disclose the loan, we REVERSE and REMAND for proceedings consistent with this opinion.

JACOB A. GOLDBERG, (David Dean, on the brief) The Rosen Law Firm, P.A., Jenkintown, PA, for Plaintiffs-Appellants.

ERIC RIEDER, (Heather S. Goldman, on the brief), Bryan Cave Leighton Paisner, LLP, New York, NY, for Defendants-Appellees.

WESLEY, Circuit Judge:

Plaintiffs-Appellants, Royce Setzer, Earl Holtzman, Dror Gronich, and Steven Klein, brought this putative class action against Omega Healthcare Investors, Inc., a publicly traded Maryland corporation that invests in healthcare facilities, and against Omega’s chief executives. Plaintiffs assert claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the “Exchange

Act”), 15 U.S.C. §§ 78j(b), 78t(a), and Rule 10b–5, 17 C.F.R. § 240.10b–5, on behalf of a putative class of investors who purchased or otherwise acquired Omega’s securities between May 3, 2017 and October 31, 2017 (the “Class Period”). Plaintiffs claim that Omega misled investors by failing to disclose a $15 million working capital loan it made to one of its major tenants, Orianna Health Systems. According to Plaintiffs, this omission hid from investors an accurate picture of Orianna’s financial difficulties. The district court dismissed the complaint, holding, inter alia, that although the non-disclosure of the loan amounted to a material omission, Plaintiffs failed to plead a strong inference that Omega acted with the requisite scienter.

Because we find that the complaint adequately alleges that Omega acted with scienter in failing to disclose the loan, we reverse the district court’s decision and remand for proceedings consistent with this opinion.

BACKGROUND

I. Facts 1 Omega is a self-administered real estate investment trust that invests in healthcare facilities, such as skilled nursing and assisted living facilities. Omega either owns the properties and leases them to the facility operators, or it provides operators with mortgage financing. Omega reports its financial performance to the market through its Funds from Operations (“FFO”) and Adjusted Funds from Operations (“AFFO”) metrics. Thus, Omega’s FFO and AFFO primarily reflect rents paid by its operators. 2

1Because we review de novo a dismissal pursuant to Federal Rule of Civil Procedure 12(b)(6), we largely take the facts from Plaintiffs’ complaint and assume them to be true. See Kalnit v. Eichler, 264 F.3d 131, 137–38 (2d Cir. 2001). 2 According to Omega’s 2017 10-K:

NAREIT [National Association of Real Estate Investment Trusts] FFO is a non-GAAP financial measure. We use NAREIT FFO as one of several criteria to measure the operating performance of our business. We further believe that by excluding the effect of depreciation, amortization, impairment on real estate assets and gains or losses from sales of real estate, all of which are based on historical costs and which may be of limited relevance in evaluating current performance, NAREIT FFO can facilitate comparisons of operating performance between periods and between other REITs.

J.A. 138.

At all relevant times, Defendant C. Taylor Pickett served as Omega’s chief executive officer; Defendant Robert O. Stephenson served as the chief financial officer; and Defendant Daniel J. Booth served as the chief operating officer (together, with Omega, “Defendants”).

By late 2016 and early 2017, Omega’s second largest operator, Orianna, 3 began experiencing severe financial difficulties and became delinquent on its rent. Orianna operated 59 skilled nursing facilities across the country, representing seven percent of Omega’s investment portfolio at that time (roughly $619 million in gross investment). In response to Orianna’s financial troubles, on May 2, 2017, Omega provided a $15 million working capital loan to the company (the “Loan”). 4 A. First Quarter: January 1, 2017 through March 31, 2017 Two days after it made the Loan, Omega held a conference call with analysts to discuss its results for the first quarter of 2017. On the call, Defendant Booth described Orianna’s “performance pressure,” which he claimed was

3 Orianna is also identified in Omega’s public filings as “New ARK Investments, Inc.,” the name of its affiliate. 4 The parties sometimes refer to the Loan as an $18.8 million line of credit. That figure includes half of the accumulated interest on the Loan. The amount disbursed, however, was $15 million.

“exacerbated” by “complete replacement of senior management” in 2016. J.A. 25 ¶ 35. Booth indicated that “[t]he new management team well known and respected by Omega worked throughout 2016 to transform the culture of the company, which included changing out many facility-level management teams.” Id. Booth acknowledged that during this “transition period” Orianna’s operational performance dipped below 1x EBITDAR 5 coverage for 2016. Id. However, in an effort to help Orianna during the transition period, Omega had “embarked on an effort to sell off [Orianna’s] northwest region, which consisted of 7 facilities,” and that “3 facilities [had] already been sold.” Id. at 25–26 ¶ 35. Defendant Pickett added that Orianna was rebranding, moving its corporate headquarters, and making significant business changes in an attempt to recover. 6

5 EBITDAR stands for earnings before interest, taxes, depreciation, amortization, and restructuring or rent cost; it measures profitability. As the district court noted, an EBITDAR below 1x “represents significant cash flow issues.” SPA-3 n.3. 6Omega’s Form 10-Q for the first quarter of 2017, filed with the SEC on May 5, 2017, described the following loss regarding Orianna’s recovery plan:

In March 2017, we executed sale agreements with two unrelated third parties to sell the 7 Northwest facilities with a carrying value of approximately $36.4 million for $34.0 million. As a result, we recorded an allowance for loss of approximately $2.4 million. For the three months ended March 31, 2017, we recognized approximately $0.8 million of direct financing lease income on a cash basis related to the Northwest facilities

Free access — add to your briefcase to read the full text and ask questions with AI

In Re Omega Healthcare Inv'rs, Inc. SEC. Litig., 968 F.3d 204 (2d Cir. 2020).

968 F.3d 204 (In Re Omega Healthcare Inv'rs, Inc. SEC. Litig.) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related